These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29022901)

  • 1. BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.
    Pereira WO; De Carvalho DD; Zenteno ME; Ribeiro BF; Jacysyn JF; Sardinha LR; Zanichelli MA; Hamerschlak N; Jones GE; Pagnano KB; Castro FA; Calle Y; Amarante-Mendes GP
    Cell Death Dis; 2017 Oct; 8(10):e3114. PubMed ID: 29022901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells.
    Nemethova V; Babiakova P; Teglasova B; Uhelska L; Babelova A; Selc M; Jakic K; Mitrovsky O; Myslivcova D; Zackova M; Poturnayova A; Batorova A; Drgona L; Razga F
    Am J Physiol Cell Physiol; 2024 Jul; 327(1):C184-C192. PubMed ID: 38826137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
    Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
    Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
    Feng H; Fu Y; Cui Z; Zhou M; Zhang L; Gao Z; Ma S; Chen C
    Br J Haematol; 2023 Sep; 202(6):1178-1191. PubMed ID: 37469124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
    Tobin LA; Robert C; Rapoport AP; Gojo I; Baer MR; Tomkinson AE; Rassool FV
    Oncogene; 2013 Apr; 32(14):1784-93. PubMed ID: 22641215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
    BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
    Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
    Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells.
    Rittavee Y; Artus J; Desterke C; Simanic I; de Souza LEB; Riccaldi S; Coignard S; Ijjeh Y; Hugues P; Bennaceur-Griscelli A; Turhan AG; Foudi A
    Exp Hematol; 2023 Feb; 118():40-52. PubMed ID: 36535407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.
    Scopim-Ribeiro R; Machado-Neto JA; Eide CA; Coelho-Silva JL; Fenerich BA; Fernandes JC; Scheucher PS; Savage Stevens SL; de Melo Campos P; Olalla Saad ST; de Carvalho Palma L; de Figueiredo-Pontes LL; Simões BP; Rego EM; Tognon CE; Druker BJ; Traina F
    Invest New Drugs; 2021 Jun; 39(3):736-746. PubMed ID: 33403501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia.
    Brumatti G; Kaloni D; Castro FA; Amarante-Mendes GP
    Biochem J; 2023 Jan; 480(2):161-176. PubMed ID: 36719792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
    Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
    Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model.
    Ye Y; Yang X; Li F; Liu W; Zhang W; Huang Z
    Animal Model Exp Med; 2024 Apr; 7(2):136-144. PubMed ID: 36300552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies.
    Younes S; Ismail MA; Al-Jurf R; Ziyada A; Nasrallah GK; Abdulrouf PV; Nagy M; Zayed H; Farrell T; Sorio C; Morsi H; Qoronfleh MW; Al-Dewik NI
    Hematology; 2023 Dec; 28(1):2196866. PubMed ID: 37078896
    [No Abstract]   [Full Text] [Related]  

  • 20. Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia.
    Hasanova A; Asadov C; Karimova N; Shirinova A; Aliyeva G; Alimirzoyeva Z
    Pathol Oncol Res; 2023; 29():1611518. PubMed ID: 38188610
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.